Pfizer

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Pfizer and other ETFs, options, and stocks.

About PFE

Pfizer Inc. is a research-based global biopharmaceutical company. It engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide.

CEO

Albert Bourla

CEOAlbert Bourla

Employees

79,000

Employees79,000

Headquarters

New York, New York

HeadquartersNew York, New York

Founded

1849

Founded1849

Employees

79,000

Employees79,000

PFE Key Statistics

Market cap

245.99B

Market cap245.99B

Price-Earnings ratio

8.57

Price-Earnings ratio8.57

Dividend yield

3.63

Dividend yield3.63

Average volume

17.98M

Average volume17.98M

High today

$44.61

High today$44.61

Low today

$43.73

Low today$43.73

Open price

$44.36

Open price$44.36

Volume

22.96M

Volume22.96M

52 Week high

$61.71

52 Week high$61.71

52 Week low

$40.94

52 Week low$40.94

PFE News

Simply Wall St 2d

Pfizer Seems To Use Debt Rather Sparingly - Simply Wall St

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility of prices, but whether you will suffer a...

Simply Wall St 4d

Pfizer Inc.'s Earnings Are Not Doing Enough For Some Investors

When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") above 14x, you may consider Pfizer Inc. (NYSE:PFE) as an attrac...

Investor's Business Daily 6d

Pfizer's Covid Sales Are Expected To Decline, Again — Is PFE Stock Now A Sell?

Pfizer stock is heading south in September after the company announced its plan to buy Global Blood Therapeutics (GBT) and won Food and Drug Administration auth...

Analyst ratings

57%

of 23 ratings

Buy

43.5%

Hold

56.5%

Sell

PFE Earnings

$0.00

$0.68

$1.36

$2.04

Q1 FY21

Q2 FY21

Q3 FY21

Q4 FY21

Q1 FY22

Q2 FY22

Q3 FY22

Estimated

— per share

Estimated— per share

Actual

Available Nov 1, Pre-Market

ActualAvailable Nov 1, Pre-Market

More PFE News

MarketWatch 6d

Pfizer and BioNTech seek authorization of omicron-targeted booster for children aged 5 to 11 - MarketWatch

Pfizer and German partner BioNTech said Monday they’re seeking Food and Drug Administration authorization for their omicron-targeting bivalent vaccine for use i...

Benzinga 7d

Pfizer/BioNTech Seek FDA Emergency Nod For Updated COVID-19 Shot For Kids Under 11 Years

Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) have completed an FDA submission seeking Emergency Use Authorization (EUA) for a 10-µg booster dose for Om...

Benzinga 7d

Pfizer CEO Contracts COVID-19 Infection For Second Time

by Pfizer Inc's PFE CEO Albert Bourla said he had tested positive for COVID-19. CEO Albert Bourla said he had tested positive for COVID-19. "I'm feeling well...

MarketWatch 7d

Pfizer, BioNTech Ask FDA to Approve Booster for Children - MarketWatch

By Dean Seal Pfizer Inc. and partner BioNTech SE have asked the U.S. Food and Drug Administration to approve the use of its Omicron-specific Covid-19 vaccine b...

Reuters 7d

Pfizer/BioNTech seek FDA nod for new COVID boosters for children - Reuters

A child receives a dose of the Pfizer-BioNTech coronavirus disease (COVID-19) pediatric vaccine during a mass vaccination program for children ages 6 to 7 in Ci...

MarketWatch 7d

Pfizer and BioNTech seek FDA EUA for omicron-targeting booster for use in children aged 5 to 11

Pfizer Inc. PFE, -1.10% and German partner BioNTech SE BNTX, -1.27% said Monday they have submitted an application to the U.S. Food and Drug Administration seek...